The year in review – New drugs and new indications in 2016: a system that favours imitation over the pursuit of real progress

Prescrire International, May 2017, Volume 26, N° 182

4 pp. 157 kB

Little therapeutic progress was made in 2016, yet many medicines with no clinical value, uncertain efficacy or an unfavourable harm-benefit balance were authorised. This is due at least in part to the current system that drives pharmaceutical research and development. The primary focus is neither on patients’ needs nor on delivering genuine therapeutic advances at affordable prices.

(Visited 31 times, 1 visits today)
This entry was posted in Essential Medicines, General. Bookmark the permalink.